DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment

European Journal of Drug Metabolism and Pharmacokinetics
Momir MikovHani Al-Salami

Abstract

The continuously increasing incidence of diabetes worldwide has attracted the attention of the scientific community and driven the development of a novel class of antidiabetic drugs that can be safely and effectively used in diabetic patients. Of particular interest in this context are complications associated with diabetes, such as renal impairment, which is the main cause of high cardiovascular morbidity and mortality in diabetic patients. Intensive control of glucose levels and other risk factors associated with diabetes and metabolic syndrome provides the foundations for both preventing and treating diabetic nephropathy. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a highly promising novel class of oral agents used in the treatment of type 2 diabetes mellitus that may be successfully combined with currently available antidiabetic therapeutics in order to achieve blood glucose goals. Beyond glycemic control, emerging evidence suggests that DPP-4 inhibitors may have desirable off-target effects, including renoprotection. All type 2 diabetes mellitus patients with impaired renal function require dose adjustment of any DPP-4 inhibitor administered except for linagliptin, for which renal excretion is a minor elimination p...Continue Reading

References

Aug 1, 1986·The Journal of Clinical Endocrinology and Metabolism·M A NauckW Creutzfeldt
Dec 1, 1967·The Journal of Clinical Investigation·M J Perley, D M Kipnis
Jan 1, 1997·Clinical Pharmacokinetics·Y W LamR L Talbert
Nov 16, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·E RitzS Halimi
Jan 10, 2002·European Journal of Pharmacology·Carol MorenoRichard J Roman
Aug 13, 2003·Kidney International·Damien du CheyronJosiane Poggioli
Oct 1, 1964·The Journal of Clinical Endocrinology and Metabolism·H ELRICKY ARAI
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Jean-Pierre GutzwillerChristoph Beglinger
Jun 24, 2004·American Journal of Physiology. Cell Physiology·Adriana C C GirardiPeter S Aronson
Jul 1, 2006·Digestion·Jean-Pierre GutzwillerChristoph Beglinger
Jun 19, 2007·Biopharmaceutics & Drug Disposition·Arthur BergmanRajesh Krishna
Dec 14, 2007·American Journal of Physiology. Renal Physiology·Adriana Castello Costa GirardiNancy Amaral Rebouças
Jan 10, 2008·Current Medical Research and Opinion·Avraham KarasikPeter P Stein
Jun 4, 2008·Diabetes, Obesity & Metabolism·J C N ChanD Williams-Herman
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jul 22, 2008·Advances in Therapy·John Doupis, Aristidis Veves
Aug 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·Albert W Dreisbach, Juan J L Lertora
Dec 17, 2008·Pharmacological Reviews·Wook Kim, Josephine M Egan
Dec 17, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Handan HeDan Howard
Jun 30, 2009·Biopharmaceutics & Drug Disposition·Holger FuchsAndreas Greischel
Oct 30, 2009·American Journal of Physiology. Renal Physiology·Anne D M Riquier-BrisonAlicia A McDonough
Jan 21, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechKlaus Wagner
Feb 26, 2011·Clinical Pharmacokinetics·David W BoultonChirag G Patel
May 20, 2011·American Journal of Physiology. Renal Physiology·Renato O CrajoinasAdriana C C Girardi
Sep 20, 2011·Pharmacotherapy·Evan M Sisson
Oct 26, 2011·The Journal of Pharmacology and Experimental Therapeutics·Wei Jing LiuTae Sun Park
Oct 27, 2011·Indian Journal of Endocrinology and Metabolism·Vishal Gupta, Sanjay Kalra
Jan 5, 2012·Advances in Therapy·Matteo MonamiEdoardo Mannucci
Feb 22, 2012·Clinical Pharmacokinetics·Yan-Ling He
Jun 30, 2012·The Journal of Clinical Endocrinology and Metabolism·Antoine MakdissiParesh Dandona
Sep 5, 2012·Nature Reviews. Endocrinology·Juris J Meier

❮ Previous
Next ❯

Citations

Aug 8, 2021·International Journal of Molecular Sciences·Diane MouradSami T Azar
Oct 17, 2020·ACS Pharmacology & Translational Science·Chhanda Charan Danta

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.